Top

Published in:

Open Access 01-12-2012 | Research article

PNPLA 3I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection

Authors: Karolina Rembeck, Cristina Maglio, Martin Lagging, Peer Brehm Christensen, Martti Färkkilä, Nina Langeland, Mads Rauning Buhl, Court Pedersen, Kristine Mørch, Gunnar Norkrans, Kristoffer Hellstrand, Magnus Lindh, Carlo Pirazzi, Maria Antonella Burza, Stefano Romeo, Johan Westin, for the NORDynamIC group

Published in: BMC Medical Genetics | Issue 1/2012

Abstract

Background

Hepatic steatosis in HCV patients has been postulated as a risk factor associated with a higher frequency of fibrosis and cirrhosis. A single genetic variant, PNPLA3 I148M, has been widely associated with increased hepatic steatosis. Previous studies of the PNPLA3 I148M sequence variant in HCV infected individuals have reported an association between this variant and prevalence of steatosis, fibrosis, and cirrhosis. To evaluate the impact of PNPLA3 I148M variant on metabolic traits and treatment response in HCV genotype 2 and 3 infected patients.

Methods

Three hundred and eighty-two treatment naïve HCV genotype 2 or 3 infected patients were included in a phase III, open label, randomized, multicenter, investigator-initiated trial (the NORDynamIC study), in which pretreatment liver biopsies were mandatory. PNPLA3I148M genotyping was performed in a total of 359 Caucasian patients.

Results

In HCV genotype 2 infected patients carrying the PNPLA3 148M allele, there was significantly increased insulin resistance (P = 0.023) and lower viral load (P = 0.005) at baseline as well as the first seven days of antiviral treatment. These results were not observed in HCV genotype 3 infected patients.

Conclusions

Our results suggest a possible association between the PNPLA3 148M allele and insulin resistance as well as baseline viral load in HCV genotype 2, but not in genotype 3.

Available only for authorised users

Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med. 2001, 345 (1): 41-52. 10.1056/NEJM200107053450107.CrossRefPubMed

Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP: Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004, 126 (2): 586-597. 10.1053/j.gastro.2003.11.020.CrossRefPubMed

Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, Pawlotsky JM, Zeuzem S, Schalm SW, Verheij-Hart E, Negro F, et al: Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat. 2007, 14 (1): 29-35. 10.1111/j.1365-2893.2006.00777.x.CrossRefPubMed

Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G: Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001, 33 (6): 1358-1364. 10.1053/jhep.2001.24432.CrossRefPubMed

Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, Carlotto A, Bozzola L, Smedile A, Negro F: Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut. 2004, 53 (3): 406-412. 10.1136/gut.2003.018770.CrossRefPubMedPubMedCentral

Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, Adinolfi LE, Asselah T, Jonsson JR, Smedile A, et al: Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006, 130 (6): 1636-1642. 10.1053/j.gastro.2006.03.014.CrossRefPubMed

Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH: Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008, 40 (12): 1461-1465. 10.1038/ng.257.CrossRefPubMedPubMedCentral

Kotronen A, Johansson LE, Johansson LM, Roos C, Westerbacka J, Hamsten A, Bergholm R, Arkkila P, Arola J, Kiviluoto T, et al: A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia. 2009, 52 (6): 1056-1060. 10.1007/s00125-009-1285-z.CrossRefPubMed

Romeo S, Sentinelli F, Dash S, Yeo GS, Savage DB, Leonetti F, Capoccia D, Incani M, Maglio C, Iacovino M, et al: Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int J Obes (Lond). 2010, 34 (1): 190-194. 10.1038/ijo.2009.216.CrossRef

10.

Speliotes EK, Butler JL, Palmer CD, Voight BF, Hirschhorn JN, Consortium G, Consortium M: CRN N: PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology. 2010, 52 (3): 904-912. 10.1002/hep.23768.CrossRefPubMedPubMedCentral

11.

Valenti L, Alisi A, Galmozzi E, Bartuli A, Del Menico B, Alterio A, Dongiovanni P, Fargion S, Nobili V: I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology. 2010, 52 (4): 1274-1280. 10.1002/hep.23823.CrossRefPubMed

12.

Qiao A, Liang J, Ke Y, Li C, Cui Y, Shen L, Zhang H, Cui A, Liu X, Liu C, et al: Mouse patatin-like phospholipase domain-containing 3 influences systemic lipid and glucose homeostasis. Hepatology. 2011, 54 (2): 509-521. 10.1002/hep.24402.CrossRefPubMed

13.

Santoro N, Kursawe R, D'Adamo E, Dykas DJ, Zhang CK, Bale AE, Calí AM, Narayan D, Shaw MM, Pierpont B, et al: A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology. 2010, 52 (4): 1281-1290. 10.1002/hep.23832.CrossRefPubMedPubMedCentral

14.

Sevastianova K, Kotronen A, Gastaldelli A, Perttilä J, Hakkarainen A, Lundbom J, Suojanen L, Orho-Melander M, Lundbom N, Ferrannini E, et al: Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. Am J Clin Nutr. 2011, 94 (1): 104-111. 10.3945/ajcn.111.012369.CrossRefPubMed

15.

Kantartzis K, Peter A, Machicao F, Machann J, Wagner S, Königsrainer I, Königsrainer A, Schick F, Fritsche A, Häring HU, et al: Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes. 2009, 58 (11): 2616-2623. 10.2337/db09-0279.CrossRefPubMedPubMedCentral

16.

Wang CW, Lin HY, Shin SJ, Yu ML, Lin ZY, Dai CY, Huang JF, Chen SC, Li SS, Chuang WL: The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Liver Int. 2011, 31 (9): 1326-1331. 10.1111/j.1478-3231.2011.02526.x.CrossRefPubMed

17.

Krawczyk M, Gruenhage F, Mahler M, Tirziu S, Acalovschi M, Lammert F: The common adiponutrin variant p.I148M does not confer gallstone risk but affects fasting glucose and triglyceride levels. J Physiol Pharmacol. 2011, 62 (3): 369-375.PubMed

18.

Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, Dongiovanni P, Maggioni M, Fracanzani AL, Rametta R, et al: Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology. 2011, 53 (3): 791-799. 10.1002/hep.24123.CrossRefPubMed

19.

Cai T, Dufour JF, Muellhaupt B, Gerlach T, Heim M, Moradpour D, Cerny A, Malinverni R, Kaddai V, Bochud M, et al: Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J Hepatol. 2011, 55 (3): 529-535. 10.1016/j.jhep.2010.12.020.CrossRefPubMed

20.

Trépo E, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, Gustot T, Lemmers A, Berthillon P, Amininejad L, Chevallier M, et al: Impact of patatin-like phospholipase-3 (rs738409 C > G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology. 2011, 54 (1): 60-69. 10.1002/hep.24350.CrossRefPubMed

21.

Corradini SG, Burza MA, Molinaro A, Romeo S: Patatin-like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma. Hepatology. 2011, 53 (5): 1776-1777. 10.1002/hep.24244. author reply 1777CrossRefPubMed

22.

Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, Dhillon AP, Alsio A, Hellstrand K, Westin J, et al: Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology. 2008, 47 (6): 1837-1845. 10.1002/hep.22253.CrossRefPubMed

23.

Bendtsen P, Karlsson N, Dalal K, Nilsen P: Hazardous Drinking Concepts, Limits and Methods: Low Levels of Awareness, Knowledge and Use in the Swedish Population. Alcohol Alcohol. 2011, 46 (5): 638-645.CrossRefPubMed

24.

DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979, 237 (3): E214-E223.PubMed

25.

Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000, 23 (1): 57-63. 10.2337/diacare.23.1.57.CrossRefPubMed

26.

Eslam M, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M: Use of HOMA-IR in hepatitis C. J Viral Hepat. 2011, 18 (10): 675-684. 10.1111/j.1365-2893.2011.01474.x.CrossRefPubMed

27.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28 (7): 412-419. 10.1007/BF00280883.CrossRefPubMed

28.

Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN: Histological grading and staging of chronic hepatitis. J Hepatol. 1995, 22 (6): 696-699. 10.1016/0168-8278(95)80226-6.CrossRefPubMed

29.

Kollerits B, Coassin S, Beckmann ND, Teumer A, Kiechl S, Döring A, Kavousi M, Hunt SC, Lamina C, Paulweber B, et al: Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins. Hum Mol Genet. 2009, 18 (23): 4669-4676. 10.1093/hmg/ddp424.CrossRefPubMedPubMedCentral

30.

Romeo S, Sentinelli F, Cambuli VM, Incani M, Congiu T, Matta V, Pilia S, Huang-Doran I, Cossu E, Loche S, et al: The 148 M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol. 2010, 53 (2): 335-338. 10.1016/j.jhep.2010.02.034.CrossRefPubMed

31.

Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001, 50 (8): 1844-1850. 10.2337/diabetes.50.8.1844.CrossRefPubMed

32.

Kotronen A, Yki-Järvinen H: Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008, 28 (1): 27-38.CrossRefPubMed

33.

Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, et al: NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002, 35 (2): 373-379. 10.1053/jhep.2002.30692.CrossRefPubMed

34.

Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, et al: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003, 37 (4): 917-923. 10.1053/jhep.2003.50161.CrossRefPubMed

35.

Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, Goto T, Westerbacka J, Sovijärvi A, Halavaara J, Yki-Järvinen H: Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002, 87 (7): 3023-3028. 10.1210/jc.87.7.3023.CrossRefPubMed

36.

Thomssen R, Bonk S, Propfe C, Heermann KH, Köchel HG, Uy A: Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol. 1992, 181 (5): 293-300. 10.1007/BF00198849.CrossRefPubMed

37.

André P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, Pol S, Bréchot C, Paranhos-Baccalà G, Lotteau V: Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol. 2002, 76 (14): 6919-6928. 10.1128/JVI.76.14.6919-6928.2002.CrossRefPubMedPubMedCentral

38.

Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M, Ye J: Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci USA. 2007, 104 (14): 5848-5853. 10.1073/pnas.0700760104.CrossRefPubMedPubMedCentral

39.

He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, Cohen JC, Hobbs HH: A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010, 285 (9): 6706-6715. 10.1074/jbc.M109.064501.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/13/82/prepub

Title: PNPLA 3I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection
Authors: Karolina Rembeck
Cristina Maglio
Martin Lagging
Peer Brehm Christensen
Martti Färkkilä
Nina Langeland
Mads Rauning Buhl
Court Pedersen
Kristine Mørch
Gunnar Norkrans
Kristoffer Hellstrand
Magnus Lindh
Carlo Pirazzi
Maria Antonella Burza
Stefano Romeo
Johan Westin
for the NORDynamIC group
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: BMC Medical Genetics / Issue 1/2012
Electronic ISSN: 1471-2350
DOI: https://doi.org/10.1186/1471-2350-13-82

At a glance: The STEP trials

Springer Medicine

PNPLA 3I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Leukotriene B4 receptor locus gene characterisation and association studies in asthma

A human MYBPC3 mutation appearing about 10 centuries ago results in a hypertrophic cardiomyopathy with delayed onset, moderate evolution but with a risk of sudden death

MC1R variants predisposing to concomitant primary cutaneous melanoma in a monozygotic twin pair

The MAP2K5-linked SNP rs2241423 is associated with BMI and obesity in two cohorts of Swedish and Greek children

UMOD as a susceptibility gene for end-stage renal disease

Left ventricular hypertrabeculation/noncompaction with epilepsy, other heart defects, minor facial anomalies and new copy number variants